Phathom Pharmaceuticals (PHAT) Common Equity (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Common Equity data on file, last reported at -$337.0 million in Q1 2026.

• On a quarterly basis, Common Equity changed 0.42% year-over-year to -$337.0 million in Q1 2026; TTM through Mar 2026 was -$337.0 million, a 0.42% change from a year earlier, with the FY2025 full-year figure at -$438.2 million, down 72.79% from the prior year.
• Common Equity for Q1 2026 stood at -$337.0 million, up from -$438.2 million in the prior quarter.
• Over the last five years, Common Equity for PHAT reached as high as $38.0 million in Q1 2022 and fell as low as -$438.2 million in Q4 2025.
• Historically, Common Equity has averaged -$176.4 million across 5 years, with a median of -$148.5 million in 2024.
• Across the five-year window, Common Equity surged 351.43% in 2023 and slumped 1428.57% in 2024, its largest moves.
• Year by year, Common Equity stood at -$74.8 million in 2022, then gained by 2.75% to -$72.8 million in 2023, then sank by 248.52% to -$253.6 million in 2024, then tumbled by 72.79% to -$438.2 million in 2025, then advanced by 23.1% to -$337.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$337.0 million in Q1 2026, -$438.2 million in Q4 2025, and -$422.5 million in Q3 2025.